In addition to causing tremendous obstetric and neonatal morbidity, pregnancy-associated malaria may have lasting consequences for the development of immunity during childhood. It has long been known that the fetal immune system is predisposed toward development of tolerance upon exposure to foreign antigens. The biological mechanisms underlying this process are only beginning to be understood, but recent data support a novel model of "layered" immune development, wherein the fetal immune system is populated during development by two distinct waves of lymphoid progenitor cells that differ in their intrinsic properties and developmental potential: "fetal" T cells (Tf), which are tolerogenic, and "adult" T cells (Ta), which are poised to mount effector responses. We propose to test this hypothesis by examining the consequences of in utero exposure to malaria antigens among infants born to women participating in two randomized trials of chemoprevention during pregnancy in a highly malaria-endemic region of Uganda. We hypothesize that fetal exposure to malaria antigens in utero can induce immune tolerance, which interferes with the later development of antimalarial immunity. We further hypothesize that infants with a Tf-skewed (predominantly tolerogenic) T cell compartment at birth will develop less robust Th1 responses and be slower to acquire natural immunity to malaria. In three aims, we will assess the relationship between in utero exposure to malaria antigens, the proportion of "tolerogenic" fetal T cells present at birth (Tf:Ta ratio), and the frequency and function of malaria-specific effector T cells and FoxP3+ regulatory CD4 T cells in cord blood, and we will determine how these factors influence the T cell response to postnatal infection and the incidence of clinical malaria during the first 3 years of life. By performing longitudinal assessments of mother-infant pairs who are followed closely from mid-gestation through early childhood and differ only in their prenatal exposure to malaria antigens, the proposed investigations will test a novel paradigm for understanding human fetal immune ontogeny and will define the immune consequences of prenatal exposure to malaria, as well the potential of chemoprevention during pregnancy to enhance antimalarial immunity during childhood.

Public Health Relevance

The proposed studies will test the impact of enhanced chemoprevention during pregnancy on the development of antimalarial immunity during infancy, and will test a novel hypothesis for human fetal immune development. A better understanding of the mechanisms underlying fetal immune tolerance to malaria could lead to improved strategies to combat childhood malaria, and may also be of great importance for infant malaria vaccination strategies.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01HD059454-07
Application #
8706921
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Jagannathan, Prasanna; Nankya, Felistas; Stoyanov, Cristina et al. (2015) IFN? Responses to Pre-erythrocytic and Blood-stage Malaria Antigens Exhibit Differential Associations With Past Exposure and Subsequent Protection. J Infect Dis 211:1987-96
Kakuru, Abel; Achan, Jane; Muhindo, Mary K et al. (2014) Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis 59:446-53
Bartelink, Imke H; Savic, Rada M; Mwesigwa, Julia et al. (2014) Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol 54:121-32
Koss, Catherine A; Natureeba, Paul; Plenty, Albert et al. (2014) Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr 67:128-35
Conrad, Melissa D; Bigira, Victor; Kapisi, James et al. (2014) Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One 9:e105690
Young, Sera L; Plenty, Albert H J; Luwedde, Flavia A et al. (2014) Household food insecurity, maternal nutritional status, and infant feeding practices among HIV-infected Ugandan women receiving combination antiretroviral therapy. Matern Child Health J 18:2044-53
Kamya, Moses R; Kapisi, James; Bigira, Victor et al. (2014) Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS 28:2701-9
Bigira, Victor; Kapisi, James; Clark, Tamara D et al. (2014) Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 11:e1001689
Ruel, Theodore D; Kakuru, Abel; Ikilezi, Gloria et al. (2014) Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 65:535-41
Ikilezi, Gloria; Achan, Jane; Kakuru, Abel et al. (2013) Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg 88:744-6

Showing the most recent 10 out of 15 publications